Phase II Study of Pembrolizumab in the Immunoreactive Ovarian Cancer Subtype
|Effective start/end date
|3/6/19 → 3/30/24
- UNIVERSITY OF CALIFORNIA, LOS ANGEL
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.